Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vitiligo - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H2 2017, provides an overview of the Vitiligo (Dermatology) pipeline landscape. Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 1 and 4 respectively. Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology). - The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Vitiligo - Overview 6 Vitiligo - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Products under Development by Companies 9 Vitiligo - Therapeutics Assessment 10 Assessment by Target 10 Assessment by Mechanism of Action 12 Assessment by Route of Administration 14 Assessment by Molecule Type 16 Vitiligo - Companies Involved in Therapeutics Development 18 Aclaris Therapeutics Inc 18 Arrien Pharmaceuticals LLC 18 Bristol-Myers Squibb Co 19 Celgene Corp 20 Clinuvel Pharmaceuticals Ltd 20 Incyte Corp 21 Vitiligo - Drug Profiles 22 abatacept - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 afamelanotide - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 apremilast - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 ARN-4079 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 ATI-50001 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 ATI-50002 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 AX-1602 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 ruxolitinib phosphate - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 VLRX-001 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Vitiligo - Dormant Projects 70 Vitiligo - Product Development Milestones 71 Featured News & Press Releases 71 Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study 71 Dec 03, 2015: Update on North American vitiligo program for SCENESSE 72 May 05, 2015: Clinuvel announces innovative melanocortin for new indications 73 Mar 20, 2015: SCENESSE vitiligo data presented at world's largest dermatology conference 74 Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology 75 May 06, 2014: Clinuvel's Phase II vitiligo study commences in Singapore 76 Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology 76 Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore 77 Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients 78 Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference 79 Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo 79 Oct 16, 2012: Observations from Clinuvels US vitiligo study published 80 Mar 15, 2012: Observations from Clinuvels vitiligo and EPP programs being presented at the 81 Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial 82 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 83 Disclaimer 84
List of Tables
Number of Products under Development for Vitiligo, H2 2017 7 Number of Products under Development by Companies, H2 2017 8 Products under Development by Companies, H2 2017 9 Number of Products by Stage and Target, H2 2017 11 Number of Products by Stage and Mechanism of Action, H2 2017 13 Number of Products by Stage and Route of Administration, H2 2017 15 Number of Products by Stage and Molecule Type, H2 2017 17 Vitiligo - Pipeline by Aclaris Therapeutics Inc, H2 2017 18 Vitiligo - Pipeline by Arrien Pharmaceuticals LLC, H2 2017 18 Vitiligo - Pipeline by Bristol-Myers Squibb Co, H2 2017 19 Vitiligo - Pipeline by Celgene Corp, H2 2017 20 Vitiligo - Pipeline by Clinuvel Pharmaceuticals Ltd, H2 2017 20 Vitiligo - Pipeline by Incyte Corp, H2 2017 21 Vitiligo - Dormant Projects, H2 2017 70
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.